Prof. Dr. Christoph Driessen
Medizinische Onkologie und Hämatologie · Dept. I
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
Jan 25, 2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Jan 25, 2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Downey-Kopyscinski S, Overkleeft H, Driessen C, Richardson P, Mitsiades C, Florea B, Bhatt A, Gautier M, Daily E, Kisselev A. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2018; 2:2443-2451.
Oct 9, 2018An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Oct 9, 2018Blood Adv 2018; 2:2443-2451
Downey-Kopyscinski Sondra, Overkleeft Herman S, Driessen Christoph, Richardson Paul G, Mitsiades Constantine S, Florea Bogdan I, Bhatt Ananta, Gautier Marc, Daily Ellen W, Kisselev Alexei F
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when
Caers J, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner H, Terpos E, Dimopoulos M, Driessen C, Larocca A, Garderet L, Kortüm K, O'Dwyer M, van de Donk N, Binder M, Dold S, Gay F, Corre J, Beguin Y, Ludwig H, Engelhardt M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018
Aug 31, 2018An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when
Aug 31, 2018Haematologica 2018
Caers Jo, Boccadoro Mario, Gramatzki Martin, Zweegman Sonja, Einsele Hermann, Cavo Michele, Goldschmidt Hartmut, Sonneveld Pieter, Delforge Michel, Auner Holger W, Terpos Evangelos, Dimopoulos Meletios A, Driessen Christoph, Larocca Alessandra, Garderet Laurent, Kortüm K Martin, O'Dwyer Michael E, van de Donk Niels W C J, Binder Mascha, Dold Sandra Maria, Gay Francesca, Corre Jill, Beguin Yves, Ludwig Heinz, Engelhardt Monika
Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. Hematol Oncol 2018
Aug 3, 2018Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
Aug 3, 2018Hematol Oncol 2018
Aeppli Stefanie, Driessen Christoph, Graf Lukas, Hitz Felicitas
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Barrio S, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou R, Braggio E, Stewart A, Raab M, Einsele H, Driessen C, Chatterjee M, Leich E, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Kortüm K. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2018
Jul 19, 2018Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Jul 19, 2018Leukemia 2018
Barrio Santiago, Martinez-Lopez Joaquin, Rosenwald Andreas, Beckmann Roland, Bargou Ralf C, Braggio Esteban, Stewart A Keith, Raab Marc S, Einsele Hermann, Driessen Christoph, Chatterjee Manik, Leich Ellen, Stühmer Thorsten, Da-Viá Matteo, Barrio-Garcia Clara, Lehners Nicola, Besse Andrej, Cuenca Isabel, Garitano-Trojaola Andoni, Fink Severin, Kortüm K Martin
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018
May 2, 2018Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
May 2, 2018Leukemia 2018
Ludwig Heinz, Cook Gordon, Leleu Xavier, Goldschmidt Hartmut, Jackson Graham, Kaiser Martin, Weisel Katja, van de Donk Niels W C J, Waage Anders, Beksac Meral, Mellqvist Ulf H, Engelhardt Monika, Caers Jo, Driessen Christoph, Bladé Joan, Mateos Maria-Victoria, Garderet Laurent, Delforge Michel, Facon Thierry, Einsele Hermann, Gay Francesca, Moreau Philippe, Avet-Loiseau Hervé, Boccadoro Mario, Hájek Roman, Mohty Mohamad, Cavo Michele, Dimopoulos Meletios A, San-Miguel Jesús F, Terpos Evangelos, Zweegman Sonja, Sonneveld Pieter
Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir. German Medicale Science, www.egms.de 2018
Jan 1, 2018Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir
Jan 1, 2018German Medicale Science, www.egms.de 2018
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2018; 121:600-9.
Jan 1, 2018Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Jan 1, 2018BJU Int 2018; 121:600-9
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Mateos M, Garderet L, Zweegman S, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Sonneveld P. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia 2017
Dec 18, 2017Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Dec 18, 2017Leukemia 2017
Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N W C J, Waage A, Beksac M, Mellqvist U H, Engelhardt M, Caers J, Driessen Christoph, Mateos M-V, Garderet L, Zweegman S, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M A, San-Miguel J F, Terpos E, Sonneveld P
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott Z, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou Q, Olsen J, Hajduch M, Cvek B, Deshaies R, Vrobel I, Dzubak P, Mistrik M, Andersen K, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017; 552:194-199.
Dec 6, 2017Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Dec 6, 2017Nature 2017; 552:194-199
Skrott Zdenek, Pouckova Pavla, Sedlacek Jindrich, Miklovicova Andrea, Kutt Anne, Li Jing, Mattova Jana, Driessen Christoph, Dou Q Ping, Olsen Jørgen, Hajduch Marian, Cvek Boris, Deshaies Raymond J, Vrobel Ivo, Dzubak Petr, Mistrik Martin, Andersen Klaus Kaae, Friis Søren, Majera Dusana, Gursky Jan, Ozdian Tomas, Bartkova Jirina, Turi Zsofia, Moudry Pavel, Kraus Marianne, Michalova Martina, Vaclavkova Jana, Bartek Jiri
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
Nov 21, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Nov 21, 2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Le Moigne R, Chesi M, Bergsagel P, Kraus M, Driessen C, Kiss von Soly S, Yakes F, Wustrow D, Shawver L, Zhou H, Martin T, Wolf J, Mitsiades C, Anderson D, Wang J, Rice J, Lam C, Aftab B, Djakovic S, Dhimolea E, Valle E, Murnane M, King E, Soriano F, Menon M, Wu Z, Wong S, Lee G, Yao B, Wiita A, Rolfe M. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther 2017; 16:2375-2386.
Sep 6, 2017The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Sep 6, 2017Mol Cancer Ther 2017; 16:2375-2386
Le Moigne Ronan, Chesi Marta, Bergsagel P Leif, Kraus Marianne, Driessen Christoph, Kiss von Soly Szerenke, Yakes F Michael, Wustrow David, Shawver Laura, Zhou Han-Jie, Martin Thomas G, Wolf Jeffrey L, Mitsiades Constantine S, Anderson Daniel J, Wang Jinhai, Rice Julie, Lam Christine, Aftab Blake T, Djakovic Stevan, Dhimolea Eugen, Valle Eduardo, Murnane Megan, King Emily M, Soriano Ferdie, Menon Mary-Kamala, Wu Zhi Yong, Wong Stephen T, Lee Grace J, Yao Bing, Wiita Arun P, Rolfe Mark
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Jul 28, 2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Jul 28, 2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
Jul 5, 2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Jul 5, 2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
Spotlight on pomalidomide: could less be more?
Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more?. Leukemia 2017; 31:1987-1989.
May 22, 2017Spotlight on pomalidomide: could less be more?
May 22, 2017Leukemia 2017; 31:1987-1989
Zander T, Aebi S, Pabst T, Renner C, Driessen Christoph
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma. Presented at: -, -
Jan 1, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L
Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Abt D, Kraus M, Bader J, Besse A, Schmid H, Engeler D, Driessen C, Besse L (2017). Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms. Presented at: -, -
Jan 1, 2017Verbesserung der Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzell-Carcinoms
Jan 1, 2017-
Abt Dominik, Kraus M, Bader J, Besse A, Schmid Hans-Peter, Engeler Daniel, Driessen Christoph, Besse L